Navigation Links
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Date:12/7/2008

r the placebo group. The infusion of avidin was well- tolerated with no allergic reactions observed.

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b ComparedWith Warfarin in Subjects With Non-Valvular Atrial Fibrillation

[Abstract #33]

Jeffrey I. Weitz, MD, HendersonResearch Centre, Hamilton, Canada

The primary objective of this study was to evaluate the safety of four dosing regimens of DU-176b in patients with non-valvular atrial fibrillation. This phase II study found that two regimens (30 mg and 60 mg once-daily) of an investigational oral Factor Xa inhibitor, DU-176b, are safe in patients with non-valvular atrial fibrillation, making the drug a potential substitute for warfarin, the conventional blood-thinning agent used in such patients to prevent stroke.

Dosing of warfarin is complicated because it interacts with many commonly-used medications and even certain foods. For that reason, patients receiving warfarin require regular blood testing to monitor the international normalized ratio (INR) to ensure that an adequate yet safe dose of warfarin is given.

A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of DU-176b (30 mg once-daily, 30 mg twice-daily, 60 mg once-daily, 60 mg twice- daily) or warfarin (dose-adjusted to a target INR of 2.0 to 3.0) for 12 weeks. The primary endpoints of the study were the incidence of bleeding events (major and clinically relevant non-major) and elevated liver enzymes and/or bilirubin, which might be indicative of hepatic toxicity. Secondary endpoints included major adverse cardiovascular events, stroke, systemic embolism, acute myocardial infarction, hospitalizations due to
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... 21 BET News correspondent, Andre Showell will lead the discussion during ... Wednesday, July 22 ( ) at 8 ... broadcast of the entire news conference along with pre and post analysis ... The President is expected to discuss health care legislation and ...
... LOUIS, July 21 Young Innovations, Inc. (Nasdaq: YDNT ) ... $0.04 per share, payable September 15, 2009 to all shareholders of record ... of up to 500,000 shares of the Company,s stock. This authorization, which ... scheduled to expire on July 31, 2009. , , ...
... , , FRANKLIN, Tenn., July 21 ... documentation technology and services, today announced details for the release of its ... , Spheris plans to issue its earnings ... trading on Thursday, August 6, 2009, and will host a conference call ...
... , , HOUSTON, July 21 ... of fiscal 2009 on Thursday, August 6, 2009. , , ... at 11 a.m. ET following distribution of the earnings release. Additional information will ... the News Room on the day of the earnings announcement. , ...
... Ill., July 21 Since 2003, the University HealthSystem Consortium (UHC) has ... the sixth consecutive year. The Honor Roll publicly recognizes and celebrates all ... , All Honor Roll recipients must exhibit 10 ... a work environment founded on dignity and respect for all employees , ...
... MEQUON, Wis., July 21 Wonderbox Technologies has ... to benefit from continued advances in technology and software features. ... designed for managed care benefit administration and case management. The ... scheduling, managing, and monitoring day-to-day care tasks and case assignments. ...
Cached Medicine News:Health News:BET Networks Airs Special Coverage of President Obama's News Conference on Health Care 2Health News:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2Health News:Spheris Sets Second Quarter 2009 Earnings Release and Conference Call Dates 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:University HealthSystem Consortium Recognized as a Company That Cares for Sixth Year in a Row 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: